Log In
BCIQ
Print this Print this
 

LAG525

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
Description mAb targeting lymphocyte-activation gene 3 (LAG3; CD223)
Molecular Target Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today